Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration

C. Turnquist, I. Horikawa, E. Foran, EO. Major, B. Vojtesek, DP. Lane, X. Lu, BT. Harris, CC. Harris,

. 2016 ; 23 (9) : 1515-28. [pub] 20160422

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011252
E-zdroje Online Plný text

NLK Free Medical Journals od 2011
PubMed Central od 2011 do Před 1 rokem
Europe PubMed Central od 2011 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Bidirectional interactions between astrocytes and neurons have physiological roles in the central nervous system and an altered state or dysfunction of such interactions may be associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Astrocytes exert structural, metabolic and functional effects on neurons, which can be either neurotoxic or neuroprotective. Their neurotoxic effect is mediated via the senescence-associated secretory phenotype (SASP) involving pro-inflammatory cytokines (e.g., IL-6), while their neuroprotective effect is attributed to neurotrophic growth factors (e.g., NGF). We here demonstrate that the p53 isoforms Δ133p53 and p53β are expressed in astrocytes and regulate their toxic and protective effects on neurons. Primary human astrocytes undergoing cellular senescence upon serial passaging in vitro showed diminished expression of Δ133p53 and increased p53β, which were attributed to the autophagic degradation and the SRSF3-mediated alternative RNA splicing, respectively. Early-passage astrocytes with Δ133p53 knockdown or p53β overexpression were induced to show SASP and to exert neurotoxicity in co-culture with neurons. Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors. Brain tissues from AD and ALS patients possessed increased numbers of senescent astrocytes and, like senescent astrocytes in vitro, showed decreased Δ133p53 and increased p53β expression, supporting that our in vitro findings recapitulate in vivo pathology of these neurodegenerative diseases. Our finding that Δ133p53 enhances the neuroprotective function of aged and senescent astrocytes suggests that the p53 isoforms and their regulatory mechanisms are potential targets for therapeutic intervention in neurodegenerative diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011252
003      
CZ-PrNML
005      
20180418124821.0
007      
ta
008      
180404s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/cdd.2016.37 $2 doi
035    __
$a (PubMed)27104929
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Turnquist, C $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
245    10
$a p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration / $c C. Turnquist, I. Horikawa, E. Foran, EO. Major, B. Vojtesek, DP. Lane, X. Lu, BT. Harris, CC. Harris,
520    9_
$a Bidirectional interactions between astrocytes and neurons have physiological roles in the central nervous system and an altered state or dysfunction of such interactions may be associated with neurodegenerative diseases, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Astrocytes exert structural, metabolic and functional effects on neurons, which can be either neurotoxic or neuroprotective. Their neurotoxic effect is mediated via the senescence-associated secretory phenotype (SASP) involving pro-inflammatory cytokines (e.g., IL-6), while their neuroprotective effect is attributed to neurotrophic growth factors (e.g., NGF). We here demonstrate that the p53 isoforms Δ133p53 and p53β are expressed in astrocytes and regulate their toxic and protective effects on neurons. Primary human astrocytes undergoing cellular senescence upon serial passaging in vitro showed diminished expression of Δ133p53 and increased p53β, which were attributed to the autophagic degradation and the SRSF3-mediated alternative RNA splicing, respectively. Early-passage astrocytes with Δ133p53 knockdown or p53β overexpression were induced to show SASP and to exert neurotoxicity in co-culture with neurons. Restored expression of Δ133p53 in near-senescent, otherwise neurotoxic astrocytes conferred them with neuroprotective activity through repression of SASP and induction of neurotrophic growth factors. Brain tissues from AD and ALS patients possessed increased numbers of senescent astrocytes and, like senescent astrocytes in vitro, showed decreased Δ133p53 and increased p53β expression, supporting that our in vitro findings recapitulate in vivo pathology of these neurodegenerative diseases. Our finding that Δ133p53 enhances the neuroprotective function of aged and senescent astrocytes suggests that the p53 isoforms and their regulatory mechanisms are potential targets for therapeutic intervention in neurodegenerative diseases.
650    _2
$a alternativní sestřih $7 D017398
650    _2
$a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
650    _2
$a amyotrofická laterální skleróza $x metabolismus $x patologie $7 D000690
650    _2
$a astrocyty $x cytologie $x účinky léků $x metabolismus $7 D001253
650    _2
$a autofagie $x účinky léků $7 D001343
650    _2
$a mozek $x metabolismus $x patologie $7 D001921
650    _2
$a kultivované buňky $7 D002478
650    _2
$a stárnutí buněk $7 D016922
650    _2
$a kokultivační techniky $7 D018920
650    _2
$a genetické vektory $x genetika $x metabolismus $7 D005822
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-6 $x genetika $x metabolismus $7 D015850
650    _2
$a leupeptiny $x farmakologie $7 D007976
650    _2
$a neurony $x cytologie $x metabolismus $7 D009474
650    _2
$a neuroprotekce $x fyziologie $7 D000066829
650    _2
$a protein - isoformy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D020033
650    _2
$a RNA interference $7 D034622
650    _2
$a malá interferující RNA $x metabolismus $7 D034741
650    _2
$a sekvestosom 1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000071456
650    _2
$a serin-arginin sestřihové faktory $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000068103
650    _2
$a nádorový supresorový protein p53 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horikawa, I $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
700    1_
$a Foran, E $u Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
700    1_
$a Major, E O $u Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
700    1_
$a Vojtesek, B $u Regional Centre for Applied and Molecular Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic.
700    1_
$a Lane, D P $u p53 Laboratory, Biomedical Sciences Institutes (A*STAR), Singapore 138648, Singapore.
700    1_
$a Lu, X $u Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, UK.
700    1_
$a Harris, B T $u Department of Neurology, Georgetown University Medical Center, Washington DC 20007, USA. Department of Pathology, Georgetown University Medical Center, Washington DC 20007, USA.
700    1_
$a Harris, C C $u Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
773    0_
$w MED00005364 $t Cell death and differentiation $x 1476-5403 $g Roč. 23, č. 9 (2016), s. 1515-28
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27104929 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418124921 $b ABA008
999    __
$a ok $b bmc $g 1288737 $s 1008064
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 23 $c 9 $d 1515-28 $e 20160422 $i 1476-5403 $m Cell death and differentiation $n Cell Death Differ $x MED00005364
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...